Search results for "hepatic"

showing 10 items of 609 documents

Congenital hepatic fibrosis: CT findings in 18 adults.

2004

To evaluate the computed tomographic (CT) findings in adult patients with pathologically proved congenital hepatic fibrosis.This was a retrospective review of congenital hepatic fibrosis cases identified at two institutions over the course of 8 years. Eight men and 10 women with an age range of 22-72 years (mean age, 39 years) were included. Contrast material-enhanced and unenhanced CT scans were obtained through the liver in all patients. Two radiologists evaluated size of and morphologic findings (atrophy or hypertrophy localized according to hepatic segments) in the liver; increased diameter or number of hepatic arteries at the hilum; presence of hepatic nodules, varices, spontaneous spl…

AdultLiver CirrhosisMalemedicine.medical_specialtyCommon Bile Duct Diseasesmedicine.medical_treatmentSplenectomyHilum (biology)Hepatic VeinsKidneyGastroenterologyHepatic ArteryAtrophyFibrosisInternal medicineHypertension PortalHumansMedicineRadiology Nuclear Medicine and imagingAgedRetrospective StudiesPortal Veinbusiness.industryHypertrophyMiddle Agedmedicine.diseaseDuctal Plate MalformationLiverPortal hypertensionCongenital hepatic fibrosisFemaleRadiologyTomography X-Ray ComputedbusinessVaricesDilatation PathologicFollow-Up Studies
researchProduct

Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience.

2012

Abstract Aims The aim of this study is to evaluate factors associated with the outcome after surgical resection and to compare the efficacy of surgery to transarterial chemoembolisation (TACE) in patients with advanced intrahepatic cholangiocarcinoma (IHC). Materials and methods 273 patients with IHC treated in our department between 1997 and 2012 were included in our study. Patients were divided according to therapy into surgical ( n  = 130), TACE ( n  = 32), and systemic chemotherapy/best supportive care ( n  = 111) groups. Clinicopathological characteristics and survival were reviewed retrospectively. Results The 1-, 3-, and 5-year survival rates in patients after surgical resection were…

AdultLiver CirrhosisMalemedicine.medical_specialtyKaplan-Meier EstimateSingle CenterCholangiocarcinomaHepatic ArteryAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorMedicineHumansChemoembolization TherapeuticLymph nodeIntrahepatic CholangiocarcinomaAgedRetrospective StudiesAged 80 and overUnivariate analysisAnalysis of Variancebusiness.industryBile ductLiver NeoplasmsRetrospective cohort studyGeneral MedicineMiddle AgedSurgerymedicine.anatomical_structureBile Ducts IntrahepaticTreatment OutcomeOncologyBile Duct NeoplasmsChemotherapy AdjuvantResection marginSurgeryFemalePositive Surgical MarginbusinessEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition.

2009

The correlation between liver stiffness, measured by transient elastography, liver fibrosis, using the histological METAVIR score, and iron overload, measured by atomic absorption spectrometry was evaluated in 56 homozygous-beta-thalassaemics. Liver stiffness increased proportionally to liver fibrosis staging (r = 0.70; P > 0.001) independently of liver iron concentration (r = 0.01; P = 0.932). The area under the receiver-operating characteristic curve for prediction of cirrhosis was 0.997 (95% confidence interval [CI]: 0.925-1.000) with cut-off of 13 kPa with 100% sensitivity (95% CI: 69.0-100.0) and 95% specificity (95% CI: 84.2-99.3). Transient elastography is a reliable non-invasive too…

AdultLiver CirrhosisMalemedicine.medical_specialtyLiver Iron ConcentrationCirrhosisIron OverloadBiopsyGastroenterologyYoung AdultInternal medicineBiopsymedicineHumansChildmedicine.diagnostic_testbusiness.industrybeta-ThalassemiaHematologyHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseConfidence intervalHemoglobinopathyLiverElasticity Imaging TechniquesFemaleTransient elastographyHepatic fibrosisbusinessEpidemiologic MethodsBritish journal of haematology
researchProduct

Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy.

2018

Background Current EASL/AASLD guidelines recommend treatment of covert hepatic encephalopathy (HE) only in symptomatic patients, for example, in those with impaired quality of life or with affected driving abilities. Goals Because testing for impaired quality of life is time consuming, the aim of the present study was to identify simple clinical predictors for poor quality of life in patients with covert HE (CHE). Study In total, 139 cirrhotic in- and outpatients without a history of overt hepatic encephalopathy were enrolled. Diagnosis of HE grade 1 (HE1) was diagnosed clinically according to the West-Haven Criteria. Critical flicker frequency and the Psychometric Hepatic Encephalopathy Sc…

AdultLiver CirrhosisMalemedicine.medical_specialtyMultivariate analysisPsychometricsMEDLINEFlicker fusion thresholdChronic liver diseaseSex FactorsQuality of lifeInternal medicineSurveys and QuestionnairesmedicineHumansIn patientProspective StudiesHepatic encephalopathyAgedAged 80 and overbusiness.industryGastroenterologyMiddle Agedmedicine.diseasePrognosisCovertHepatic EncephalopathyPractice Guidelines as TopicQuality of LifeAccidental FallsFemalebusinessJournal of clinical gastroenterology
researchProduct

Focal lesions in cirrhosis: Not always HCC.

2017

Even though most hepatocellular carcinomas (HCC) develop in the setting of cirrhosis, numerous other focal liver lesions and pseudolesions may be encountered. The role of the radiologist is therefore to differentiate these lesions from HCC to avoid under- and overdiagnosis. There are several ways of classifying these lesions: those which predate the development of fibrosis and cirrhosis (cystic lesions, hemangioma), those related to or a consequence of cirrhosis (regenerative nodules, dysplastic nodules, focal fibrosis, peribiliary cysts, shunts, or even cholangiocarcinoma), and those related to the underlying cause of chronic liver disease (lymphoma). Finally, some may develop independentl…

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyCirrhosisCarcinoma HepatocellularBile Duct NeoplasmChronic liver disease030218 nuclear medicine & medical imagingHemangiomaCholangiocarcinomaDiagnosis Differential03 medical and health sciences0302 clinical medicineFibrosismedicineHumansRadiology Nuclear Medicine and imagingOverdiagnosisAgedAged 80 and overmedicine.diagnostic_testbusiness.industryCystsLiver NeoplasmsMagnetic resonance imagingGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance Imagingdigestive system diseasesBile Ducts IntrahepaticBile Duct Neoplasms030211 gastroenterology & hepatologyFemaleRadiologyDifferential diagnosisbusinessHemangiomaTomography X-Ray ComputedEuropean journal of radiology
researchProduct

Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospect…

2013

Abstract OBJECTIVES: The occurrence of decompensation marks a crucial turning point in the course of cirrhosis. The purpose of this study was to assess the risk of mortality according to the clinical characteristics of first decompensation, considering also the impact of acute-on-chronic liver failure (AoCLF). METHODS: We conducted a prospective nationwide inception cohort study in Italy. Decompensation was defined by the presence of ascites, either overt or detected by ultrasonography (UD), gastroesophageal variceal bleeding (GEVB), and hepatic encephalopathy (HE). AoCLF was defined according to the Asian Pacific Association for the Study of the Liver criteria. Multivariable Cox proportion…

AdultLiver CirrhosisMalemedicine.medical_specialtyPediatricsCarcinoma HepatocellularCirrhosisAdolescentmedicine.medical_treatmentCirrhosis Mortality Liver decompensation CohortLiver transplantationEsophageal and Gastric VaricesSeverity of Illness IndexYoung AdultSeverity of illnessmedicineHumansProspective StudiesYoung adultIntensive care medicineProspective cohort studyHepatic encephalopathyAgedProportional Hazards ModelsAged 80 and overFirst episodeHepatologybusiness.industryLiver NeoplasmsGastroenterologyAscitesMiddle Agedmedicine.diseaseLiver TransplantationAdolescent; Adult; Aged; Aged 80 and over; Ascites; Carcinoma Hepatocellular; Esophageal and Gastric Varices; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Italy; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Severity of Illness Index; Young AdultItalyCirrhosisHepatic EncephalopathyMultivariate AnalysisCohortFemaleGastrointestinal HemorrhagebusinessLiver FailureFollow-Up Studies
researchProduct

Diagnostic value of MR-based texture analysis for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD)

2019

PurposeTo investigate the performance of MR-based texture analysis (TA) for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).MethodsFifty-four adult patients (33 females, 21 males, mean age 49.813.5years) with biopsy-proven NAFLD were enrolled and underwent MR imaging on a 1.5T system. TA parameters were extracted on axial noncontrast 3D-GRE T1W images (slice thickness=4.6mm) using a commercially available research software (TexRAD). Receiver operating curves (ROC), areas under the ROC (AUROC) and 95% confidence intervals (CI) were calculated to assess the accuracy of each TA parameter for the diagnosis of significant (F2) and advanced fibrosis (F…

AdultLiver CirrhosisMalemedicine.medical_specialtyUrologyGastroenterology030218 nuclear medicine & medical imaging03 medical and health sciencesImaging Three-Dimensional0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisInternal medicineImage Interpretation Computer-AssistedNonalcoholic fatty liver diseaseHumansNonalcoholic fatty liver diseaseMedicineRadiology Nuclear Medicine and imagingIn patientTexture analysiAgedRetrospective StudiesRank correlationRadiological and Ultrasound Technologymedicine.diagnostic_testbusiness.industryGastroenterologyMagnetic resonance imagingMiddle AgedHepatologymedicine.diseaseMagnetic Resonance ImagingConfidence intervalLiverMagnetic resonance030220 oncology & carcinogenesisElasticity Imaging TechniquesFemaleSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessHepatic fibrosisHepatic fibrosisSoftwareAbdominal Radiology
researchProduct

Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis.

2011

Up to 4 million persons in the USA have chronic hepatitis C (CHC) (1). Despite a decline in overall HCV infections, the number of patients with end stage liver disease due to CHC will increase for the next 2 decades (2). Even with highly effective novel therapies, currently 30–50% of infected individuals fail treatment (3). Therefore, a better understanding of mechanisms involved in CHC-related liver disease progression could permit more efficient therapies. Adaptive effector T cells (frequently assessed by measuring production of prototypic T helper 1 cytokine IFNγ) play an important role in control of HCV infection during the acute phase (4). In CHC, effector HCV-specific T cell immune re…

AdultLiver CirrhosisMalemedicine.medical_treatmentT cellGene ExpressionHepacivirusBiologyCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryCollagen Type IArticleInterferon-gammaImmune systemTransforming Growth Factor betamedicineHepatic Stellate CellsCytotoxic T cellHumansIL-2 receptorAgedHepatologyViral Core ProteinsFOXP3Hepatitis C ChronicMiddle AgedInterleukin-10Collagen Type I alpha 1 ChainInterleukin 10Cytokinemedicine.anatomical_structureCross-Sectional StudiesLiverImmunologyDisease ProgressionFemaleMatrix Metalloproteinase 1CD8Hepatology (Baltimore, Md.)
researchProduct

Serum nitrotyrosine and psychometric tests as indicators of impaired fitness to drive in cirrhotic patients with minimal hepatic encephalopathy

2013

BACKGROUND & AIMS: Cirrhotic patients with minimal hepatic encephalopathy (MHE) show impaired driving ability and increased vehicle accidents. The neurological deficits contributing to impair driving and the underlying mechanisms are poorly understood. Early detection of driving impairment would help to reduce traffic accidents in MHE patients. It would be therefore useful to have psychometric or biochemical parameters reflecting driving impairment. The aims of this work were as follows: (i) to shed light on the neurological deficits contributing to impair driving; (ii) to assess whether some psychometric test or biochemical parameter is a good indicator of driving impairment. METHODS: We a…

AdultLiver Cirrhosismedicine.medical_specialtyAutomobile DrivingCirrhosisPsychometricsEncephalopathyPoison controlminimal hepatic encephalopathyAudiologyNitric Oxidepsychometric testsFlicker FusionmedicineHumansHepatic encephalopathyCyclic GMPAgedPsychomotor learning3-nitrotyrosineAnalysis of VarianceHepatologybusiness.industryDriving simulatorMiddle Agedmedicine.diseaseAnticipationfitness to driveMotor coordinationHepatic EncephalopathyPhysical therapyTyrosineChemokinesbusinesshuman activitiesBiomarkers
researchProduct

Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II …

2019

Abstract Background Hepatic arterial embolisation therapy (HAET) is a treatment of liver metastases of gastrointestinal neuroendocrine tumours (GI-NETs). HAET increases circulating vascular endothelial growth factor levels. Everolimus is a treatment in NETs that may have antiangiogenic activity. Methods This phase II study was conducted in patients with predominant and progressive liver metastases from GI-NETs. Everolimus was initiated 7–30 days after HAET. The hypothesis was that everolimus after HAET would increase hepatic progression-free survival (hPFS) rate at 24 months from 35% to 50%. Results Among the 74 patients included, 88% had small-bowel primary tumour, 43% had grade I and 57% …

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyLung NeoplasmsPhases of clinical researchAntineoplastic AgentsBone NeoplasmsGastroenterologyStreptozocin03 medical and health scienceschemistry.chemical_compoundHepatic Artery0302 clinical medicineInternal medicineMucositisHumansMedicineIn patientEverolimusChemoembolization TherapeuticTrial registrationPeritoneal NeoplasmsAgedGastrointestinal NeoplasmsAged 80 and overGastrointestinal tractAntibiotics AntineoplasticEverolimusbusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseaseEmbolization TherapeuticProgression-Free SurvivalConfidence intervalVascular endothelial growth factorNeuroendocrine Tumors030104 developmental biologyOncologychemistryDoxorubicin030220 oncology & carcinogenesisFemaleLymph Nodesbusinessmedicine.drugEuropean Journal of Cancer
researchProduct